Education and the internet should ease recruitment drought Public education campaigns and more sophisticated web-based tools are needed to overcome barriers to patient recruitment for clinical trials, a new report suggests.As many as 90% of trials suffer delays and the majority of...
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Suppressed HIV-1 Viral Load and Increa ISENTRESS(R) (raltegravir), Merck's first-in-class HIV-1 integrase inhibitor, suppressed HIV-1 viral load and increased CD4 cell counts through 48 weeks of combination therapy with other anti-HIV medicines compared to placebo in combination...
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day - CombinatoRx, Incorporated (NASDAQ: CRXX) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA...
Cholesterol-Lowering Drugs Decrease Coronary Artery Disease, But Not Aortic Valve Disease A recent study found intensive LDL-cholesterol lowering with the combination of the drugs simvastatin and ezetimibe in patients with mild to moderate aortic stenosis does appear to reduce the risk of coronary artery disease events, but does...
Epidemiology and BI: Help for Designing Effective Intelligence Faithful readers of the OpenBI Forum over the last 28 months have probably noticed two common themes to the columns.The first is guidance for business intelligence (BI) from outside business, particularly academic areas such as statistics...
Seattle Genetics Inc. Q2 2008 Earnings Call Transcript Good afternoon ladies and gentlemen.Thank you for standing by.
Welcome to the Seattle Genetics second quarter 2008 financial results conference call.
(Operator instructions) This conference is being recorded today, Tuesday July 22,...
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day CombinatoRx, Incorporated (NASDAQ: CRXX) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA....
CombinatoRx Highlights Progress in Key Programs at 2008 R&D Day CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX - News) today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its...
Biogen IDEC, Inc. Q2 2008 Earnings Call Transcript James C.Mullen - President and CEO Bill Sibold - Sr.
VP, US Commercial Al Sandrock - Sr.
VP, Neurology Research and Development Paul J.
Clancy - EVP and CFO Analysts Michael Aberman - Credit Suisse Geoffrey Meacham - JPMorgan Yaron...
Using Earned Value Analysis to manage clinical trial accruals ClearTrial Clinical Trial Budgeting and Accruals Expert to Speak at IIR Cost & Contract Management Conference ClearTrial to present Streamlining Accruals & Contract Management with Earned Value Analysis CHICAGO,...
Emergent BioSolutions and the University of Oxford form joint venture to develop an advanced Tuberculosis vacc Wellcome Trust and Aeras Global TB Vaccine Foundation have agreed to provide GBP 8 million in funding for Phase IIb clinical trial that is expected to commence in 2009 -- The vaccine candidate, MVA85A, has been granted orphan drug...
Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vacc -- Wellcome Trust and Aeras Global TB Vaccine Foundation have agreed to provide GBP 8 million in funding for Phase IIb clinical trial that is expected to commence in 2009 -- The vaccine candidate, MVA85A, has been granted orphan drug...
Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vacc - The University of Oxford and Emergent BioSolutions Inc.(NYSE:EBS) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd.
(the 'Consortium'), to further develop MVA85A, the world's most...
Using Earned Value Analysis to manage clinical trial accruals ClearTrial Clinical Trial Budgeting and Accruals Expert to Speak at IIR Cost & Contract Management Conference ClearTrial to present Streamlining Accruals & Contract Management with Earned Value Analysis CHICAGO, July 20,...
Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vacc The University of Oxford and Emergent BioSolutions Inc.(NYSE:EBS) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd.
(the 'Consortium'), to further develop MVA85A, the world's most...
Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV www.gilead.com- Gilead Sciences, Inc.Susan Hubbard, 650-522-5715 (Investors) Amy Flood, 650-522-5643 (Media) Gilead Sciences, Inc.
(Nasdaq:GILD) today announced that it has begun enrolling patients in a Phase III clinical trial of...
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer an Study Demonstrates Feasibility and Efficacy of Treating Patients with Primary Liver Cancer SAN FRANCISCO, and YONGIN-SI, South Korea, July 22 /PRNewswire/ -- Jennerex, Inc.(San Francisco, CA and Ottawa, Ontario), and its South Korean...
Cancer Treatment Guide Article - Cancer Treatment: A Beginner's Guide Learn about the basic types of cancer treatments, including surgery, radiation, chemotherapy, and hormone therapy.Article - Cancer Symptoms: A Beginner's Guide Early detection matters --...
Advexin Shows Statistically Significant Six-Month and Overall Survival Benefit as Compared to Methotrexate in Supplemental Findings Presented at American Association for Cancer Research's Cancer Clinical Trials and Personalized Medicine Conference AUSTIN, Texas--(BUSINESS WIRE)--July 23, 2008--Introgen Therapeutics, Inc.(NASDAQ:INGN),...
Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium dif SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc.(Nasdaq:OPTR - News) today announced that the company has completed enrollment in the first of two pivotal Phase 3 clinical trials evaluating the safety and efficacy of OPT-80...
Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV - Gilead Sciences, Inc.(Nasdaq:GILD) today announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is...
Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium dif - Optimer Pharmaceuticals, Inc.(Nasdaq:OPTR) today announced that the company has completed enrollment in the first of two pivotal Phase 3 clinical trials evaluating the safety and efficacy of OPT-80 for the treatment of Clostridium...
Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium dif Author : CA-OPTIMER-PHARMA Category : Press Release News Alerts by Email click here ) News | Home SAN DIEGO - (Business Wire) Optimer Pharmaceuticals, Inc.(Nasdaq:OPTR) today announced that the company has completed enrollment in the...
ADVEXIN(R) Shows Statistically Significant Six-Month and Overall Survival Benefit as Compared to Methotrexate Supplemental Findings Presented at American Association for Cancer Research's Cancer Clinical Trials and Personalized Medicine Conference AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc.(NASDAQ:INGN - News), a...
Gilead Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV FOSTER CITY, Calif.-(Business Wire)-July 22, 2008 - Gilead Sciences, Inc.(Nasdaq:GILD) today announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS...
